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Hereditary spastic paraplegias (HSPs), characterized by progressive and bilateral spasticity of the legs, are usually caused by developmen-
tal failure or degeneration of motor axons in the corticospinal tract. There are considerable interfamilial and intrafamilial variations in
age at onset and severity of spasticity. Genetic studies also showed that there are dozens of genetic loci, on multiple chromosomes, that
are responsible for HSPs. Through linkage study of a pedigree of HSP with autosomal-dominant inheritance, we mapped the causative
gene to 3q24-q26. Screening of candidate genes revealed that the HSP is caused by a missense mutation in the gene for acetyl-CoA trans-
porter (SLC33A1). It is predicted that the missense mutation, causing the change of the highly conserved serine to arginine at the codon
113 (p. S113R), disrupts the second transmembrane domain in the transporter and reverses the orientation of all of the descending
domains. Knockdown of Slc33a1 in zebraﬁsh caused a curve-shaped tail and defective axon outgrowth from the spinal cord. Although
the wild-type human SLC33A1 was able to rescue the phenotype caused by Slc33a1 knockdown in zebraﬁsh, the mutant SLC33A1
(p.S113R) was not, suggesting that S113R mutation renders SLC33A1 nonfunctional and one that wild-type allele is not sufﬁcient for
sustaining the outgrowth and maintenance of long motor axons in human heterozygotes. Thus, our study illustrated a critical role of
acetyl-CoA transporter in motor-neuron development and function.Characterized by progressive and bilateral spasticity of the
legs, the hereditary spastic paraplegias (HSPs) are a highly
heterogeneous group of neurodegenerative disorders that
are usually caused by developmental failure or degenera-
tion of motor axons in the corticospinal tract.1,2 Clinically,
HSPs can be classiﬁed into uncomplicated or complicated
form, depending on whether spasticity occurs in isolation
(uncomplicated HSP) or is associated with additional
symptoms, such as mental retardation, deafness, cerebellar
ataxia, epilepsy, dysarthria, and ichthyosis (complicated
HSP).2 The uncomplicated HSP, which is more common
than the complicated HSP, usually presents four core fea-
tures of HSP: a slowly progressive spastic gait, an increased
muscle tone in the lower limbs, hyperreﬂexia, and exten-
sor plantar responses. Although patients with uncompli-
cated HSP generally have the core clinical features, consid-
erable variation in age at onset and severity of spasticity
has been observed both within and between families.1–3
Genetic studies have showed that HSPs are also extremely
heterogeneous with autosomal dominant (AD), autosomal
recessive (AR), and X-linked inheritance.2–4 To date, 38
HSP loci and 19 spastic-paraplegia genes have been identi-
ﬁed, according to the HUGO and OMIM databases.2,3
Among them, SPASTIN (SPG4) (MIM 604277),5 ATLASTIN
(SPG3A) (MIM 606439),6 NIPA1 (SPG6) (MIM 600363),7
KIAA0196 (SPG8) (MIM 603563),8 KIF5A (SPG10) (MIM
604187),9 HSP60 (SPG13) (MIM 605280),10 REEP1 (SPG31)
(MIM 610250),11 and ZFYVE27 (SPG33) (MIM 610244)12752 The American Journal of Human Genetics 83, 752–759, Decembhave been associated with AD HSP. Mutations in the genes
SPASTIN (SPG4), ATLASTIN (SPG3), and REEP1 (SPG31)
account for the majority of AD forms of HSP.2,13,14 Muta-
tions in KIF5A, HSP60, KIAA0196, and NIPA1 each occur
in < 1% of HSP cases.
Clinical Features
We were contacted by a family member of a large kindred
with HSP for genetic counseling. The disease clearly fol-
lowed a pattern of AD inheritance, though with incom-
plete penetrance (Figure 1). We set out to conduct a genetic
study of this family. The study was approved by the Ethics
Committee of the Shandong University School of Medi-
cine, and informed consent was obtained from all partici-
pants. Clinical examinations of 57 subjects in the family
were performed by an experienced neurologist (C.Y). On
the basis of the clinical examination, the subjects were
scored as deﬁnitely affected (all four core features of HSP—
spasticity, increased muscle tone, hyperreﬂexia, and exten-
sor plantar reﬂexes—were present), unaffected, or mildly
affected (with only one or two core feature[s] of HSP). Sum-
marized in Table 1 are the clinical features of all patients.
The age at onset was listed according to the self-report of
affected subjects. Of the 57 family members examined,
20 individuals were diagnosed as deﬁnitely affected and
three (III-8, IV-12, and V-1) as mildly affected, displaying
lower-limb hyperreﬂexia or mild spastic gait alone. As
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Figure 1. The Pedigree of a Large Family with Hereditary Spastic Paraplegia and the Haplotypes of Markers Spanning the Linked
Region on Chromosome 3q24-q26
Filled squares and circles indicate definitely affected, hatched squares indicate mildly affected. The haplotype segregating with HSP is
boxed. SPG42 is flanked by D3S2326 and D3S3053.the affected. This variation is not unexpected for AD HSP,
partly because mild symptoms, which can progress slowly,
might go unnoticed for years. A probable case of incom-
plete penetrance was also noticed for III-22. Whereas his
daughter, IV-14, is deﬁnitely affected, with spastic paraple-
gia that started when she was 8 years old, III-22 is asymp-
tomatic and shows no abnormal features upon neurologi-
cal examination at age 43. No additional neurological
symptoms were detected in this family. Two affected fam-
ily members, IV-4 and IV-14, were further examined by
electromyography (EMG), magnet resonance imaging
(MRI), and muscle biopsy, and no abnormalities were de-
tected. Therefore, the patients in this pedigree might repre-
sent those with an uncomplicated form of HSP.
Linkage Studies
Blood samples were obtained from 21 family members
(17 deﬁnitely affected, three mildly affected, and one unaf-
fected) and seven spouses (all unaffected), and leukocyte
genomic DNA was extracted via standard techniques. We
ﬁrst tested, by linkage analysis, whether the HSP in this
family was caused by a mutation in any of the known
HSP loci. In view of the high variability in phenotype
and the age-dependent penetrance of AD HSP, pairwise
logarithm of odds (LOD) scores were calculated with a con-
servative approach, in which only deﬁnitely affected sub-The Americanjects and unaffected spouses were included in the analysis.
Linkage to any of the known AD HSP loci was excluded.
Negative LOD scores, as well as obligate recombinants in
patients, were observed for all tested loci (Table S1, avail-
able online). Subsequently, we performed a genome-wide
scan using 200 microsatellite markers spaced, on average,
15–20 cM apart on autosomes. Among the 205 markers
genotyped, six markers produced positive LOD scores, of
which two mapped to chromosome 3q and the other
four were on chromosome 4 (D4S2431), 6 (D6S1959),
7 (D7S2201), and 20 (D20S162) (Table S2). The regions sur-
rounding these loci were then further analyzed with addi-
tional microsatellite markers at a higher density. For the
regions on chromosomes 4, 6, 7, and 20, all additional
markers analyzed generated LOD scores less than 2. In
contrast, seven additional markers genotyped on chromo-
some 3q gave signiﬁcant pairwise LOD scores > 3, with
a peak of 5.085 at q ¼ 0 for D3S1746, showing strong evi-
dence of linkage between the chromosomal region and
the disease (Table 2). Multipoint linkage analysis with the
use of 11 markers on chromosome 3q reached a peak
LOD score betweenD3S2326 andD3S3053 (Figure 2). Hap-
lotype analysis indicated that all of the markers ﬂanked
by D3S2326 and D3S3053 cosegregated with the disease
(Figure 1). This 22 cM interval ﬂanked by D3S2326 and
D3S3053 corresponds to a physical distance of 27.54 Mb.Journal of Human Genetics 83, 752–759, December 12, 2008 753
Table 1. A Summary of Clinical Features Observed in Patients of a Chinese Family with HSP
Patient Sex
Age at
Examination (Yrs)
Age at
Onset (Yrs)
Disability
Gradesa Spastic Gait
Increased
Tone in LL
Hyperreflexia
in LL
Weakness
in LL
Wasting
in LL
Extensor
Plantar Reflex Pes Cavus
II-6 F 75 4 3 þþþ þ þ þ þ þ 
II-10 M 72 30 3 þþ þ þ þ þ þ 
III-1 M 56 12 3 þþ þ þ þ þ þ 
III-3 F 69 10 4 þþþ þ þ þ þ þ þ
III-5 F 63 42 2 þþ þ þ þ þ þ þ
III-7 M 50 11 3 þþ þ þ þ þ þ þ
III-8 M 43 26 1 þ þ     
III-11 F 36 13 1 þ þ þ þ  þ 
III-16 F 56 9 3 þþ þ þ þ þ þ þ
III-18 F 51 4 1 þ þ þ   þ 
III-25 F 36 20 1 þ þ þ   þ 
IV-1 M 43 11 3 þþþ þ þ þ þ þ 
IV-2 M 40 4 3 þþþ þ þ þ þ þ þ
IV-3 M 36 7 4 þþþ þ þ þ þ þ þ
IV-4 M 41 40 1 þ þ þ þ  þ þ
IV-5 M 38 10 1 þ þ þ þ þ þ 
IV-6 F 21 8 1 þ þ þ þ þ þ þ
IV-11 F 31 11 2 þþ þ þ þ  þ 
IV-12 M 27 20 1    þ   
IV-13 M 26 15 1 þ þ þ þ þ þ 
IV-14 F 20 8 2 þþ þ þ þ  þ þ
V-1 M 9 9 1 þ  þ    
‘‘’’ indicates absent, ‘‘þ’’ indicates mild, ‘‘þþ’’ indicates moderate, and ‘‘þþþ’’ indicates severe. ‘‘LL’’ denotes lower limbs.
a Disability grades: 1, no mobility problems or slight stiffness of the legs; 2, moderate gait stiffness; 3, problems running but able to walk alone; 4,
problems walking; 5, wheelchair-bound.These results clearly establish the existence of a locus for
AD HSP within chromosome 3q24-q26. This locus was
named SPG42, in accordance with HUGO nomenclature.
Mutation Analysis
A total of 130 transcripts have been mapped to the 22 cM
interval containing the SPG42 locus (UCSC Genome
Browser), none of which stood out as a clear candidate
Table 2. Two-Point LOD Score for Linkage between the HSP
Locus and Markers on Chromosome 3q24-q26
Marker
Position
Za at q ¼ 0cM Mb
D3S1764 152.62 140.67 7.710
D3S1512 158.38 145.82 7.547
D3S2326 159.8 145.69 1.532
D3S2394 160.4 147.03 3.035
D3S1744 161.04 148.57 3.569
D3S1746 169.6 153.21 5.085
D3S1545 173.72 163.15 5.069
D3S1543 173.84 162.15 5.068
D3S3052 174.94 165.68 5.045
D3S1763 176.54 168.72 4.975
D3S3053 181.87 173.23 0.797
a A gene frequency of 0.0001 and a penetrance of 90% were assumed for
the disease locus. Marker order and genetic distances were based on the
chromosome 3 genetic map of the Center for Medical Genetics at the Marsh-
field Medical Research Foundation.754 The American Journal of Human Genetics 83, 752–759, Decemfor the disease. We selected a group of genes, on the basis
of their expression pattern in neuron and their possible rel-
evance to the disease, for mutation analysis. The coding
region, exon-intron boundaries, and 50- and 30-UTRs of
the candidate genes (Figure 3A) were ampliﬁed by PCR
from genomic DNA of one patient and sequenced. The
obtained DNA sequences were compared with GenBank
sequences by BLAST. No noticeable mutation was found
in the ﬁrst ﬁve genes sequenced (PFN2 [MIM 176590,
GenBank accession number NM_053024], SCHIP1
[MIM 611622, GenBank accession number NM_014575],
SLITRK3 [MIM 609679, GenBank accession number
NM_014926], MYNN [MIM 606042, GenBank accession
number NM_018657], CLDN11 [MIM 601326, GenBank
accession number NM_005602]). However, sequence anal-
ysis of SLC33A1 (MIM 603690, GenBank accession number
NM_004733) revealed a heterozygous c.339 T/G trans-
version in exon 1. This substitution was not present in
the unaffected spouses (Figure 3B). Because the c.339T/
G single-nucleotide change did not result in a gain or
loss of a restriction site, we used an allele-speciﬁc tetra-
primer PCR assay to determine whether the mutant
G allele cosegregated with the disease. Sequencing analysis
of 35 DNA samples from affected subjects and controls
conﬁrmed the validity of the tetra-primer PCR assay (data
not shown). As shown in Figure 3C, the mutant G allele
was present in all of the deﬁnitely affected individuals
tested but not in any of the unaffected spouses. This
mutant G allele was also present in three mildly affectedber 12, 2008
subjects and in III-22, a likely obligate carrier given that he
has an affected daughter. Furthermore, the G allele was ex-
cluded as a SNP, because it was not detected in a panel of
200 normal, unrelated, ethnically matched controls (i.e.,
400 chromosomes). Together, our genetic data strongly im-
plicated the c.339T/G transversion in exon 1 of SLC33A1
as the causative mutation.
SLC33A1 encodes the acetyl-CoA transporter, which
consists of 549 amino acids and contains multiple trans-
membrance domains, with a leucine zipper motif in trans-
membrane domain III.15,16 The c.339T/G transversion in
exon 1 resulted in a missense mutation that changed ser-
ine to arginine at the codon 113 (p. S113R). The effect of
this variation on gene function was predicted to be non-
neutral by the SNAP program and to be probably damaging
by the PolyPhen program. In silico topology prediction,
with SOSUI software, indicated that SLC33A1 contains
12 transmembrane domains. The S113 residue of SLC33A1
is located at the beginning of the second transmembrane
domain. The SOSUI software predicted that the S113R
mutation would dislodge the second transmembrane do-
main (Figure 3D), leading to its expulsion from the mem-
brane bilayer. Furthermore, it would also cause all domains
starting from 113R to be placed in an opposite orientation
across the membrane when compared to the normal trans-
porter (Figure 3D). Cross-species alignment of the amino
acid sequences for SLC33A1 also shows that the serine
at position 113 is highly conserved among vertebrates
(Figure 3E). Thus, the S113R mutation probably renders
SLC33A1 nonfunctional and leads to a functional haploin-
sufﬁciency in the heterozogtes. Alternatively, S113R could
act as a dominant-negative mutation in causing the phe-
notypes in the heterozygotes. However, as shown below
in the functional study of S113R in zebraﬁsh, the latter
was less likely.
Effect of SLC33A1 Mutation on Zebraﬁsh
Development
Zebraﬁsh have recently been used in the study of patholog-
ical mechanisms underlying HSP.8,17 Decreased levels of
Figure 2. Multipoint Linkage Analysis for Markers on
Chromosome 3q24-q26
SPG4 in the developing zebraﬁsh embryos were shown
to cause motor-axon-speciﬁc outgrowth defects that
can only be rescued by wild-type SPG4, not by mutated
SPG4.17 Similar phenotype was observed when SPG8
was knocked down.8 Considering that SLC33A1 is ubiq-
uitously expressed and that human and zebraﬁsh
SLC33A1 proteins are 69% identical, we used zebraﬁsh
as a model to test the function of slc33a1 and the con-
sequence of the missense mutation S113R. First, we de-
termined whether reduced levels of SLC33A1 would
affect the development of zebraﬁsh. An antisense mor-
pholino (MO) was designed to speciﬁcally inhibit trans-
lation of zebraﬁsh slc33a1 mRNA (50-TGTGAGAGATTCA
GACAGTTC(CAT)C-30), and a 5 bp mismatch control
(TGTcAGAcATTCAcACAcTTC(gAT)C) was used to titer a
MO-speciﬁc nontoxic injection dose. The speciﬁcity and
validity of slc33a1 MO and control MO were veriﬁed by
TNT Quick Coupled Translation System (Promega) (data
not shown). Slc33a1 MO or control MO was injected into
embryos at one- to four-cell stage, and embryos were al-
lowed to develop until the desired stage. Approximately
78% (n ¼ 216) of embryos injected with slc33a1 MO sur-
vived, compared to 91% (n ¼ 256) survival when injected
with the same concentration of control MO. Among the
slc33a1MO-injected embryos that survived, many showed
curve-shaped tails similar to those observed in SPG4 and
SPG8 MO knockdown experiments in the zebraﬁsh.8,17
As shown in Figure 4A, at 36 hr after fertilization (hpf),
dechorionated wild-type zebraﬁsh had a straight tail (Fig-
ure 4Aa) and no signiﬁcant change was observed in the
ﬁsh injected with mismatch control MO (Figure 4Ab). In
contrast, slc33a1 MO-injected ﬁsh exhibited severely or
slightly curly tail phenotypes (Figures 4Ac and 4Ad). When
the injected embryos were divided into four categories—
normal, slightly curly tail, severely curly tail, and lethal-
ity—at 36 hpf, 50.5% (109/216) embryos were observed
as having a slightly curly tail and 22.2% (48/216) as having
a severely curly tail in the slc33a1 MO-injected group, in
comparison to 12.5% (32/256) and 10.9% (28/256), respec-
tively, in the control MO-injected group. Next, we deter-
mined whether human SLC33A1 could correct the defects
observed in slc33a1 MO-injected zebraﬁsh. One- to four-
cell embryos were injected with a mixture of slc33a1 MO
and full-length human SLC33A1 mRNA, which is not rec-
ognized by the slc33a1 MO. In contrast to the high per-
centage, 72.7%, of embryos with abnormal tails occurring
when slc33a1 MO alone was injected, coinjection of hu-
man SLC33A1 mRNA and slc33a1 MO reduced the per-
centage of embryos with abnormal tails to 24.4%, which
was comparable to that in the control MO-injected group,
23.4% (Figures 4Ae, 4Af, and 4B). These results suggest that
the increased occurrence of the curved-tail phenotype wasThe American Journal of Human Genetics 83, 752–759, December 12, 2008 755
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caused by a reduction of slc33a1 protein and that human
SLC33A1mRNA can compensate for the loss of the endog-
enous zebraﬁsh mRNA.
If the defects observed in slc33a1MO-injected ﬁsh reﬂect
spastic paraplegia in humans, it should be predicted that
the mutant SLC33A1 that causes HSP would not be able to
rescue the developmental defect caused by slc33a1 knock-
down. Indeed, when slc33a1 MO and human mRNA with
S113R mutation were coinjected, the frequency of tail
abnormality was not signiﬁcantly different from that in
slc33a1 MO injection alone, indicating that the human
SLC33A1 with S113R mutation can not compensate for
the loss of the endogenous zebraﬁsh mRNA. Furthermore,
injection of S113R mutant mRNA alone did not cause an
increase in the occurrence of developmental defects (Fig-
ure 4B), suggesting that S113R mutation might not act in
a dominant-negative manner.
HSPs are caused by developmental failure or degenera-
tion of motor axons in the corticospinal tract.1,2 To deter-
mine whether the tail abnormality and impaired mobility
observed upon slc33a1 knockdown were due to motor-
axon defects, we examined the motor axon by staining
embryos with an antibody against acetylated tubulin,
which marks the growing spinal motor neurons. As shown
in Figure 4Cb, by 36 hpf, spinal motor neurons in slc33a1
MO embryos were scarce and poorly organized, in contrast
to the orderly downward outgrowth from the spinal cord
observed in embryos injected with a control MO (Fig-
ure 4Ca), indicating that inhibition of slc33a1 signiﬁcantly
impaired outgrowth of motor axons. Furthermore, the mo-
tor-axon defects could be rescued by wild-type human
SCL33A1 mRNA (Figure 4Cc) but not by mutant human
SLC33A1 mRNA (Figure 4Cd).
Therefore, the results obtained with zebraﬁsh substanti-
ated the notion that S113R in SCL33A1 is a loss-of-func-
tion mutation. The fact that spastic paraplegia manifests
in S113R heterozygous individuals suggests that SLC33A1
is haploinsufﬁcient. Acetyl-CoA transporter, the protein
product of SLC33A1, is positioned to carry acetyl-CoA
into the lumen of Golgi apparatus, where acetyl-CoA is
transferred to the sialyl residues of gangliosides and glyco-
proteins.15,16 The modiﬁcation of gangliosides and glyco-
proteins by acetylation probably plays a critical role inThe Americanthe outgrowth and maintenance of the axons of the motor
neurons. Inadequate supply of acetyl-CoA, as caused by
a reduced ﬂow of acetyl-CoA into the Golgi apparatus,
can result in misprocessing of gangliosides and glycopro-
teins. Additional work is obviously needed to elucidate
the molecular mechanism of the protein and to determine
how it relates to other proteins implicated in HSP during
the disease development. As more genes causing HSP
are identiﬁed, we will have a better understanding of the
molecular pathology of HSP.
Supplemental Data
Supplemental Data include three tables and can be foundwith this
paper online at http://www.ajhg.org/.
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(A) The candidate region of 27.54 Mb between D3S2326 and D3S3053. The candidate genes screened are shown at the bottom. The
location of SLC33A1 is highlighted.
(B) Partial sequence chromatograms of exon 1 of SLC33A1 in a patient and a healthy control. The arrows mark the position of the SLC33A1
mutation. Sequence analysis was done on an ABI 3100 automated sequencer (Applied Biosystems).
(C) Confirmation of the c.339T/G mutation by allele-specific tetra-primer PCR assay. All definitely affected and mildly affected individ-
uals exhibited the G allele. Primers sequences are as follows: forward outer primer 50-GTGCCCTTATCGCTCTGA-30, reverse outer primer
50-GTGTTATTTGATGGGTTGC-30, forward inner primer (G allele) 50-TTAGCTATACAGACCAAGCTTTCTTCGGG-30, and reverse inner primer (T allele)
50-TTGAGACTGAAGGGCCAAAAGACAGAA-30.
(D) Topological prediction of the mutant SLC33A1 protein, with use of the SOSUI program. The S113R mutation resulted in the loss of the
original second TM motif and reversed the orientation of all domains, starting from 113. Upper panel, normal SLC33A1; bottom panel,
mutant SLC33A1 (S113R). The mutated amino acid is indicated by the red arrow.
(E) Amino acid sequence alignment of human SLC33A1 and orthologs from other species, showing phylogenetic conservation of S113. The
sequences were retrieved from the Entrez protein database and aligned to each other with the use of Clustal W.Journal of Human Genetics 83, 752–759, December 12, 2008 757
Figure 4. Rescue of slc33a1 Knockdown-Induced Abnormal-Tail Phenotype in Zebrafish by Wild-Type, But Not Mutant, Human
SLC33A1 mRNA
(A) Morphological features of zebrafish at 36 hpf from knockdown and rescue experiments. a, Untreated wild-type zebrafish; b, Zebrafish
injected with mismatch control MO; c and d, Slc33a1 MO-injected zebrafish with severely curved tail (c) and slightly curved tail (d); e and f,
zebrafish coinjected with slc33a1 MO and wild-type human SLC33A1 mRNA—the curly-tail phenotype was rescued completely (e) and
partially (f); g and h, zebrafish coinjected with slc33a1 MO and mutated human SLC33A1 mRNA, with severely curved tail (g) or slightly
curved tail (h). Scale bar: represents 1 mm.
(B) Phenotype profile from zebrafish knockdown and rescue experiments. The embryos were classified as normal, slightly curly tail,
severely curly tail, and lethality, and the percentage for each group is shown.
(C) Defective motor-neuron outgrowth in the reduction of slc33a1. Spinal motor axons were stained with an anti-acetylated tubulin
antibody at 36 hr after fertilization. a, motor neurons in spinal cord of zebrafish injected with mismatch control MO; b, injection of
slc33a1 MO dramatically impaired outgrowth of motor axons from the spinal cord; c, coinjection of human wild-type SLC33A1 mRNA
with slc33a1 MO rescued motor-axon defects; d, Coinjection of mutated human SLC33A1 mRNA did not rescue motor axon defects. Scale
bar represents 50 mm.References
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